C. Haqq

680 total citations
21 papers, 522 citations indexed

About

C. Haqq is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, C. Haqq has authored 21 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in C. Haqq's work include Prostate Cancer Treatment and Research (13 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Cancer Treatment and Pharmacology (6 papers). C. Haqq is often cited by papers focused on Prostate Cancer Treatment and Research (13 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Cancer Treatment and Pharmacology (6 papers). C. Haqq collaborates with scholars based in United States, France and Belgium. C. Haqq's co-authors include P K Donahoe, Michael A. Weiss, Howard I. Scher, Thian Kheoh, Johann S. de Bono, Karim Fizazi, A. Molina, William C. Hyun, Peter M. Loomer and Mark I. Ryder and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

C. Haqq

21 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Haqq United States 10 275 185 137 117 108 21 522
Stanislav Lechpammer United States 10 126 0.5× 136 0.7× 25 0.2× 88 0.8× 51 0.5× 29 439
Yasunori Harada Japan 10 195 0.7× 160 0.9× 83 0.6× 74 0.6× 58 0.5× 23 447
Jean Kao United States 10 249 0.9× 286 1.5× 39 0.3× 136 1.2× 184 1.7× 12 559
Harry Fisher United States 8 164 0.6× 136 0.7× 30 0.2× 45 0.4× 50 0.5× 11 442
Robert Shearer United Kingdom 16 334 1.2× 300 1.6× 129 0.9× 87 0.7× 116 1.1× 33 804
Irene Rainville United States 11 198 0.7× 158 0.9× 121 0.9× 146 1.2× 20 0.2× 22 423
Tommi J. Ahonen Finland 9 163 0.6× 271 1.5× 167 1.2× 120 1.0× 174 1.6× 11 589
E Gubała Poland 14 60 0.2× 276 1.5× 113 0.8× 88 0.8× 386 3.6× 37 702
Stacy Mosier United States 9 360 1.3× 275 1.5× 95 0.7× 258 2.2× 18 0.2× 9 747
Ulrich Bonk Germany 9 52 0.2× 233 1.3× 107 0.8× 147 1.3× 25 0.2× 15 437

Countries citing papers authored by C. Haqq

Since Specialization
Citations

This map shows the geographic impact of C. Haqq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Haqq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Haqq more than expected).

Fields of papers citing papers by C. Haqq

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Haqq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Haqq. The network helps show where C. Haqq may publish in the future.

Co-authorship network of co-authors of C. Haqq

This figure shows the co-authorship network connecting the top 25 collaborators of C. Haqq. A scholar is included among the top collaborators of C. Haqq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Haqq. C. Haqq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wainberg, Zev A., Colin D. Weekes, Muhammad Furqan, et al.. (2025). Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nature Medicine. 31(11). 3648–3653. 7 indexed citations
2.
3.
Jones, Jeremy O., Michael Diamond, C. Haqq, et al.. (2014). Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. Prostate Cancer and Prostatic Diseases. 17(3). 292–299. 8 indexed citations
4.
Ryan, Christopher, Thian Kheoh, C. Haqq, et al.. (2014). Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer and Prostatic Diseases. 17(2). 192–198. 28 indexed citations
5.
Sternberg, Cora N., A. Molina, Scott North, et al.. (2012). Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Annals of Oncology. 24(4). 1017–1025. 70 indexed citations
6.
7.
8.
9.
10.
11.
12.
Harland, S. J., Johann S. de Bono, C. Haqq, et al.. (2011). 7001 ORAL Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study. European Journal of Cancer. 47. S484–S484. 8 indexed citations
13.
14.
Fleisher, Martin, Daniel C. Danila, M. Leversha, et al.. (2009). Circulating tumor cells (CTC) in patients with metastatic castration-resistant prostate cancer (CRPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy. Journal of Clinical Oncology. 27(15_suppl). 5049–5049. 2 indexed citations
15.
Danila, Daniel C., Dana E. Rathkopf, M. J. Morris, et al.. (2008). Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 5019–5019. 22 indexed citations
16.
Tolcher, A. W., Mace L. Rothenberg, Jordi Rodón, et al.. (2007). A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 3002–3002. 66 indexed citations
17.
Scott, Janet H., et al.. (2006). Gene expression profiling of circulating tumor cells from breast cancer patients. Journal of Clinical Oncology. 24(18_suppl). 10769–10769. 1 indexed citations
18.
Rubenstein, James L., Angela Shen, Lauren E. Abrey, et al.. (2004). Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 22(14_suppl). 6593–6593. 1 indexed citations
19.
Ryder, Mark I., William C. Hyun, Peter M. Loomer, & C. Haqq. (2003). Alteration of gene expression profiles of peripheral mononuclear blood cells by tobacco smoke: implications for periodontal diseases. Oral Microbiology and Immunology. 19(1). 39–49. 43 indexed citations
20.
Haqq, C., et al.. (1993). SRY recognizes conserved DNA sites in sex-specific promoters.. Proceedings of the National Academy of Sciences. 90(3). 1097–1101. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stanislav Lechpammer Breakdown of academic impact, for papers by Yasunori Harada Breakdown of academic impact, for papers by Jean Kao Breakdown of academic impact, for papers by Harry Fisher Breakdown of academic impact, for papers by Robert Shearer Breakdown of academic impact, for papers by Irene Rainville Breakdown of academic impact, for papers by Tommi J. Ahonen Breakdown of academic impact, for papers by E Gubała Breakdown of academic impact, for papers by Stacy Mosier Breakdown of academic impact, for papers by Ulrich Bonk
Rankless by CCL
2026